Hostname: page-component-6898cfcb55-zsp5v Total loading time: 0 Render date: 2026-11-12T02:46:46.452Z Has data issue: false hasContentIssue false
  • English
  • Français

64 Benzodiazepine derivatives consumption in the Republic of Croatia in 2005, 2006 and 2007

Published online by Cambridge University Press:  24 June 2014

P. Draganic,
S. Zezelic,
V. Macolic-Sarinic and
S. Tomic
P. Draganic
Affiliation:
Medical department, Agecy for medicinal products and medical devices Ksaverska cesta 4, 10000 Zagreb, Croatia, E-mail: pero.draganic@almp.hr
S. Zezelic
Affiliation:
Medical department, Agecy for medicinal products and medical devices Ksaverska cesta 4, 10000 Zagreb, Croatia, E-mail: pero.draganic@almp.hr
V. Macolic-Sarinic
Affiliation:
Medical department, Agecy for medicinal products and medical devices Ksaverska cesta 4, 10000 Zagreb, Croatia, E-mail: pero.draganic@almp.hr
S. Tomic
Affiliation:
Medical department, Agecy for medicinal products and medical devices Ksaverska cesta 4, 10000 Zagreb, Croatia, E-mail: pero.draganic@almp.hr
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Introduction/Objectives:

Benzodiazepine derivatives are drugs used to relieve anxiety, muscle spasms, and seizures and to control agitation caused by alcohol withdrawal. A review of the cost and consumption for all medicines and benzodiazepine derivatives in Croatia in 2005–2007 periods, as well as the data on medicine usage for these two groups are obtained. The importance of collecting data on benzodiazepine derivatives consumption is in correlation with the improvement on antipsychotic/anxiolytic therapy.

Participants, Materials/Methods:

Agency for Medicinal Products and Medical Devices in Croatia is authorized for collecting and processing data on medicines consumption. Data on medicine usage between 2005 and 2007 was gathered from obliged entities, processed by the DDD/1000inh/day and ATC classification, and the analysis of the financial indicators was done as well.

Results:

It was established that the total medicines market in Croatia in 2005 was €520 million and 8.5% DDD/1000inh/day for benzodiazepine derivatives N05BA+N05CD groups, in 2006 it was €562 million and 8.53% DDD/1000inh/day for N05BA + N05CD groups, and in 2007 it was €670 million and 9.37% DDD/1000inh/day for N05BA+N05CD groups. By processing consumption data as DDD/1000inh/day, between 2005 and 2007 consumption of N05BA+ N05CD groups were 55.15, 59.37 and 76.5 DDD/1000inh/day, respectively. Expenditure of benzodiazepine derivatives individually was as follows: diazepam was at the first place (20.71 in 2005, 23.02 in 2006 and 23.42 DDD/1000inh/day in 2007. Alprazolam was at the second place (13.99 in 2005, 16.14 in 2006 and 16.9 DDD/1000inh/day in 2007.

Conclusions:

During the period 2005–2007, all benzodiazepine derivatives, which were in the market in Croatia, showed a continuous increase in prescribed DDD/1000inh/day. For the entire period diazepam and alprazolam were the most prescribed drugs. By collecting and analyzing data useful for the improvement of pharmacotherapy, we also obtain information for the many other factors essential for the rational health care.